REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study

Table 1

Baseline characteristics of the patients.

Characteristics	N = 45, No. (%)
Age at mRCC diagnosis, median (range), yr.	59 (42–90)
Gender
Female	16 (36)
Male	29 (64)
Smoking status at RCC diagnosis
No	24 (59)
Former/active	17 (41)
Missing	4
Histology
Clear cell	41 (91)
Papillary	1 (2)
Other	3 (7)
Fuhrman or ISUP nuclear grade
Low grade (1-2)	8 (21)
High grade (3-4)	30 (79)
Missing	7
Associated sarcomatoid tumor
No	36 (88)
Yes	5 (12)
Missing	4
Nephrectomy
No	6 (13)
Yes	39 (87)
Timing of nephrectomy
Early nephrectomy (at diagnosis)	39 (100)
Local stage	31 (79)
Metastatic stage	8 (21)
Delayed nephrectomy (after systemic treatment)	0 (0)
NA	6
Total number of treatment lines, median (range).	5 (2–10)

mRCC, metastatic renal cell carcinoma; RCC, renal cell carcinoma; ISUP, International Society of Urological Pathology.